Revefenacin in Inhalation
Phase 3Small molecule
Revefenacin in Inhalation is one of 33 small molecule programs targeting Respiratory insufficiency. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Revefenacin in Inhalation
MMylan Pharma UK Ltd.
Phase 3
Flovent
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Duragesic
CCephalon
Preclinical
Coumadin
AAbbott
Preclinical
Narcan
SScienture
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Revefenacin in Inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMylan Pharma UK Ltd.